Slow generic uptake, reformulations, follow-on products and new market entrants will ensure steady long-term growth of the epilepsy market despite several high profile patent expiries. UCB has emerged as the number one epilepsy company, and is set to strengthen their epilepsy pipeline if the proposed acquisition of Schwarz is confirmed.
Scope
Analysis of patient potential, unmet needs and clinical trial design in epilepsy
Overview of drugs in pre-registration, Phase III, II and I; with analysis of key companies involved in the market
Detailed profiles of key compounds in development for use in epilepsy, with forecasts of drug revenues to 2015
Discussion of UCB, Eisai, and GSK's strategies and insight from key industry opinion leaders
Highlights
Following on from Keppra's commercial success, UCB is the current epilepsy market leader. UCB's existing relationship with neurologists will bode well for the potent follow-on compounds, brivaracetam and seletracetam.
UCB's proposed acquisition of Schwarz will further boost its epilepsy pipeline and CNS marketing/sales capabilities. If the acquisition is completed, Datamonitor believes that UCB will continue to develop Schwarz's Phase III pipeline product lacosamide.
Generic incursion in the epilepsy market is less profound than in other CNS sectors. Nevertheless, lifecycle management strategies will be necessary to maintain market share following patent expiries. For example, development of sustained release/extended release formulations such as GSK's Lamictal XR can slow generic incursion.
Reasons to Purchase
Understand unmet needs in the epilepsy market based on key opinion leader comments
Benchmark key late-stage epilepsy compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
(0 items)
